Kiniksa Pharmaceuticals International, plc (KNSA), a biopharmaceutical company, reported first-quarter 2026 financial results reflecting revenue growth and improved earnings. In addition, the firm raised its full-year 2026 ARCALYST-based net product revenue guidance and provided recent highlights.
Following the news, KNSA is surging 16.18% at $50.67.
Company Profile
Kiniksa focuses on immune-inflammatory diseases, particularly cardiovascular conditions.
The firm offers FDA-approved ARCALYST for recurrent pericarditis, cryopyrin-associated periodic syndromes (CAPS), including Familial Cold Autoinflammatory Syndrome and Muckle-Wells Syndrome, and deficiency of IL-1 receptor antagonist (DIRA).
Kiniksa's development pipeline includes the monoclonal antibodies KPL-387 and KPL-1161.
First Quarter 2026 Results
For the first quarter of 2026, net income jumped to $22.59 million, or $0.27 per share, from $8.54 million, or $0.11 per share, in the prior year.
Total revenue increased to $214.27 million compared to $137.79 million a year ago.
As of March 31, 2026, Kiniksa had $468.1 million of cash, cash equivalents, and short-term investments and no debt.
Looking ahead to 2026, Kiniksa raised its ARCALYST net product revenue guidance to $930 million to $945 million, up from prior guidance of $900 million to $920 million.
Pipeline Highlights
KPL-387
KPL-387 is a monoclonal antibody targeting the IL-1 receptor.
Kiniksa is conducting a Phase 2/3 clinical trial of KPL-387 in recurrent pericarditis and expects data from the Phase 2 dose-focusing portion of the trial in the second half of 2026.
In addition, the company also expects to initiate the Phase 3 pivotal portion by the end of 2026.
KPL-1161
KPL-1161 is a monoclonal antibody currently in preclinical development, with a target quarterly subcutaneous (SC) dosing schedule. The company expects to initiate a Phase 1 first-in-human clinical trial by the end of 2026.
KNSA has traded between $22.23 and $52.49 over the last year. The stock closed Monday's trade at $43.61.
For More Such Biotech Stock News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.